Surf Bio

Surf Bio is a preclinical biopharmaceutical company founded in 2021 by Bryan Mazlish and Dr. Jennifer Schneider, who previously established Bigfoot Biomedical and Mode AGC. The company's genesis is rooted in commercializing a drug delivery technology developed at Stanford University. CEO Bryan Mazlish transitioned from a successful career in quantitative finance, where he founded the automated trading company Overlook Capital, to the life sciences after a family diagnosis of Type 1 Diabetes. This personal connection led him to create novel insulin delivery systems and co-found Bigfoot Biomedical in 2014. President & Chief Medical Officer Dr. Jennifer Schneider, a Stanford-trained physician, also founded Mode AGC, an insulin dosing algorithm company that was later acquired.

The company operates in the biopharmaceutical sector, focusing on transforming the delivery of biologics like monoclonal antibodies (mAbs). Its business model centers on leveraging its proprietary technology platform through collaborations with multinational pharmaceutical companies, aiming to enhance their product pipelines. Surf Bio seeks partnerships with API manufacturers to provide advanced subcutaneous delivery options for their therapeutics, targeting areas such as oncology, infectious diseases, and diabetes.

Surf Bio's core offering is the SnapShot™ technology platform, designed to overcome challenges in administering biologics. This platform utilizes a proprietary polymer to create ultra-high concentration formulations of mAbs and other biologics, enabling doses that would typically require hours-long intravenous infusions to be delivered in seconds via a single, standard subcutaneous autoinjector. A key feature is its ability to produce formulations with concentrations exceeding 600 mg/mL. This allows for at-home self-administration, potentially reducing the burden on healthcare facilities and improving patient accessibility. The technology also enhances the stability of biologics at higher temperatures, which could reduce the need for refrigeration, and is compatible with standard manufacturing processes without requiring specialized delivery devices. The company has received significant funding, including a $16 million seed round in April 2022 and a $1.6 million grant from the Bill & Melinda Gates Foundation in April 2024.

Keywords: drug delivery, biologics, monoclonal antibodies, subcutaneous injection, autoinjector, polymer technology, high-concentration formulations, pharmaceutical partnerships, biopharmaceutical, drug stabilization, preclinical, IV to SC conversion, Bryan Mazlish, Jennifer Schneider, SnapShot technology, thermostability, home administration, oncology, infectious diseases, gene therapy, ultra-rapid insulin, Stanford University spin-out, drug reformulation